Financial Performance - The company's revenue for Q3 2025 reached ¥1,388,559,655.82, representing a 26.02% increase year-over-year[5] - Net profit attributable to shareholders was ¥52,983,487.04, up 51.56% compared to the same period last year[5] - The basic earnings per share (EPS) increased by 51.60% to ¥0.1325[5] - The company reported a 19.06% increase in revenue for the year-to-date period, totaling ¥3,892,464,110.99[9] - Total operating revenue for the current period reached ¥3,892,464,110.99, an increase of 19.0% compared to ¥3,269,282,916.66 in the previous period[17] - Net profit for the current period was ¥171,391,855.81, representing a 47.8% increase from ¥115,866,292.21 in the previous period[18] - The total comprehensive income for the current period was ¥172,955,454.44, an increase from ¥116,167,189.21 in the prior period, reflecting strong overall performance[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,368,961,609.98, reflecting an 11.20% increase from the end of the previous year[5] - The company's total assets increased to ¥5,368,961,609.98, up from ¥4,828,108,351.67, reflecting a growth of 11.2%[17] - Total liabilities rose to ¥3,208,878,911.48, compared to ¥2,767,673,601.70, marking an increase of 15.9%[17] - The company’s total liabilities increased, with accounts payable rising by 84.93% to ¥604,765,667.15, attributed to increased inventory and acquisitions[9] - The equity attributable to shareholders of the parent company reached ¥2,096,021,280.80, up from ¥2,005,289,910.33, a growth of 4.5%[17] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥589,977,142.98, up 49.80%[5] - Cash inflow from operating activities totaled ¥3,942,292,569.80, up from ¥3,498,385,903.66, indicating a year-over-year increase of about 12.7%[19] - Net cash flow from operating activities reached ¥589,977,142.98, compared to ¥393,835,456.88 in the previous period, reflecting a growth of approximately 50%[19] - Cash outflow for investment activities was ¥2,164,027,213.18, significantly higher than ¥1,212,534,520.06 from the previous year, resulting in a net cash flow from investment activities of -¥650,893,558.76[20] - Cash inflow from financing activities was ¥514,448,065.00, down from ¥676,175,143.34, leading to a net cash flow from financing activities of -¥54,262,128.84[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,098[11] - The largest shareholder, He Jiale, holds 50.12% of shares, totaling 200,493,326 shares, with 51,000,000 shares pledged[11] Investment and Expenses - Operating costs rose by 17.57% to ¥2,597,540,141.10, driven by increased sales revenue[10] - Research and development expenses for the current period were ¥22,553,167.86, slightly up from ¥21,099,674.53, indicating a focus on innovation[17] - The company experienced a significant increase in investment income, which rose by 263.54% to ¥4,548,916.76 due to increased bank wealth management purchases[10] - The company reported an investment income of ¥4,548,916.76, compared to ¥1,251,299.74 in the previous period, showing significant improvement[18] Current Assets and Inventory - The company’s cash and cash equivalents decreased from ¥999,693,750.44 to ¥780,713,180.51, a decline of approximately 21.9%[15] - Accounts receivable increased from ¥454,170,194.23 to ¥536,525,781.59, representing an increase of about 18.2%[15] - Inventory rose significantly from ¥863,841,347.62 to ¥1,029,783,710.68, marking an increase of approximately 19.2%[15] - The total amount of current assets is ¥2,708,150,834.44, compared to ¥2,597,385,352.74 at the beginning of the period, an increase of approximately 4.3%[15] Other Information - The company has no preferred shareholders as of the reporting period[13] - The company has no long-term receivables or long-term equity investments reported[15] - The third quarter financial report was not audited, indicating that the figures may be subject to adjustments[21]
华人健康(301408) - 2025 Q3 - 季度财报